Brief: Qualigen Therapeutics Announces Pre-IND Feedback From U.S. Food And Drug Administration Regarding QN-302 For The Treatment Of G4-Targeted Advanced Solid Tumors
07/12/2022 14:33
Dec 7 (Reuters) - Qualigen Therapeutics Inc QLGN.O :
* QUALIGEN THERAPEUTICS ANNOUNCES PRE-IND FEEDBACK FROM U.S.
FOOD
AND DRUG ADMINISTRATION REGARDING QN-302 FOR THE TREATMENT OF
G4-TARGETED ADVANCED SOLID TUMORS
* QUALIGEN THERAPEUTICS INC- REMAIN ON TRACK TO SUBMIT IND
APPLICATION AROUND FIRST HALF OF 2023
* QUALIGEN THERAPEUTICS INC- FDA'S RESPONSE PROVIDES CO WITH
CLEAR
GUIDANCE FOR FORMALLY SUBMITTING AN IND APPLICATION FOR QN-302
Source text for Eikon: ID:nGNX9z3tfZ
Further company coverage: QLGN.O
Recent news on Aixcrypto Holdings
See all newsBrief: Aixcrypto - Enters Common Shares Purchase Agreement With Gold King Arthur Holding - SEC Filing
Chief Executive Officer And Director
Brief: Aixcrypto Holdings - Enters Note Purchase Agreement With CABG Acquisition Corp On May 12, 2026 - SEC Filing
Brief: Aixcrypto Holdings Reports First Quarter 2026 Results
AIxCrypto Q1 net loss widens as expenses rise